The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men - PubMed (original) (raw)
Randomized Controlled Trial
. 2010 Aug;95(8):3955-64.
doi: 10.1210/jc.2010-0102. Epub 2010 Jun 9.
Affiliations
- PMID: 20534765
- PMCID: PMC2913038
- DOI: 10.1210/jc.2010-0102
Randomized Controlled Trial
The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men
Kishore M Lakshman et al. J Clin Endocrinol Metab. 2010 Aug.
Abstract
Background: During testosterone (T) therapy, T is partly converted to 17beta-estradiol (E2) and 5alpha-dihydrotestosterone (DHT). Effects of age, testosterone dose, and body composition on total and free E2 and DHT levels are unknown.
Objective: We evaluated age and dose-related differences in E2 and DHT levels in response to graded doses of testosterone enanthate in young and older men.
Methods: Fifty-one young (aged 19-35 yr) and 52 older (aged 59-75 yr) men completed treatment with monthly injections of a GnRH agonist plus randomly assigned weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg) for 5 months.
Results: During testosterone administration, total and free E2 levels increased dose-dependently (dose effect, P<0.001) in both young and older men. Total and free E2 levels and E2:T ratios during T administration were higher in older than young men, but age-related differences in free E2 and free E2:T ratios were not significant after adjusting for testosterone levels, percentage fat mass, and SHBG. DHT levels and DHT:T ratios were dose-related but did not differ between young and older men. Mechanistic modeling of free hormone data revealed that the conversions of T to E2 and DHT were both consistent with saturable Michaelis-Menten kinetics. The in vivo Km values were estimated to be 1.83 nm for aromatase and 3.35 nm for 5alpha-reductase, independent of age. The Vmax parameter for E2 was 40% higher in older men than younger men, but Vmax for DHT was not significantly different between age groups.
Conclusions: During im testosterone administration, E2 and DHT levels exhibit saturable increases with dose. The rate of whole body aromatization is higher in older men, partly related to their higher percentage fat mass, SHBG, and testosterone levels.
Figures
Figure 1
Serum E2, DHT, E2:T ratios, and DHT:T ratios in response to administration of graded doses of TE in young (black bars) and older men (white bars). If there was a significant age effect, the values for young and older men for each dose were compared using t tests. The asterisk indicates significant differences between young and older men receiving that dose (P < 0.05). A, A dose-dependent increase in serum total E2 (left) and free E2 (right) levels with a significant age and dose effect. B, A dose-dependent increase in serum total DHT (left) and free DHT (right) levels with a significant dose effect only. C, A dose-dependent decrease in total E2:total T (left) and free E2:free T (right) ratios with a significant age and dose effect. D, A dose-dependent decrease in serum total DHT:total T (left) and free DHT:free T ratios (right) with a significant dose effect only. To convert total testosterone to nanomoles per liter, multiply by 0.03467; to convert free testosterone to picomoles per liter, multiply by 3.467. To convert estradiol concentrations to picomoles per liter, multiply by 3.671. To convert total DHT to nanomoles per liter, multiply by 0.0344; to convert free DHT to picomoles per liter, multiply by 3.44.
Figure 2
The relationship of total E2 and total DHT to total testosterone (TT) concentrations at baseline (symbol X) or during treatment (Tx; symbol ○) with graded doses of testosterone in young men (A and C) and older men (C and D). Dashed lines are derived from fitting all data points to a Michaelis-Menten (MM) mechanistic model (see Appendix A for details).
Figure 3
The relationship of free E2 (FE2) and free DHT (FDHT) to free testosterone (FT) concentrations at baseline (symbol X) or during treatment (Tx; symbol ○) with graded doses of testosterone in young men (A and C) and older men (C and D). Dashed lines are derived from fitting all data points to a Michaelis-Menten (MM) mechanistic model (see Appendix A for details).
Similar articles
- Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men.
Yeap BB, Alfonso H, Chubb SA, Handelsman DJ, Hankey GJ, Norman PE, Flicker L. Yeap BB, et al. J Clin Endocrinol Metab. 2012 Nov;97(11):4030-9. doi: 10.1210/jc.2012-2265. Epub 2012 Sep 13. J Clin Endocrinol Metab. 2012. PMID: 22977273 - Metabolism of sex steroids is influenced by acquired adiposity-A study of young adult male monozygotic twin pairs.
Vihma V, Naukkarinen J, Turpeinen U, Hämäläinen E, Kaprio J, Rissanen A, Heinonen S, Hakkarainen A, Lundbom J, Lundbom N, Mikkola TS, Tikkanen MJ, Pietiläinen KH. Vihma V, et al. J Steroid Biochem Mol Biol. 2017 Sep;172:98-105. doi: 10.1016/j.jsbmb.2017.06.007. Epub 2017 Jun 13. J Steroid Biochem Mol Biol. 2017. PMID: 28619249 - Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM. Traish AM. Adv Exp Med Biol. 2017;1043:473-526. doi: 10.1007/978-3-319-70178-3_22. Adv Exp Med Biol. 2017. PMID: 29224108 Review. - Sex steroids and cardiovascular disease.
Yeap BB. Yeap BB. Asian J Androl. 2014 Mar-Apr;16(2):239-47. doi: 10.4103/1008-682X.122357. Asian J Androl. 2014. PMID: 24407188 Free PMC article. Review.
Cited by
- Immunological and mass spectrometric assays of SHBG: consistent and inconsistent metabolic associations in healthy men.
Veldhuis JD, Bondar OP, Dyer RB, Trushin SA, Klee EW, Singh RJ, Klee GG. Veldhuis JD, et al. J Clin Endocrinol Metab. 2014 Jan;99(1):184-93. doi: 10.1210/jc.2013-2642. Epub 2013 Dec 20. J Clin Endocrinol Metab. 2014. PMID: 24203061 Free PMC article. - Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit.
Howard EE, Margolis LM, Berryman CE, Lieberman HR, Karl JP, Young AJ, Montano MA, Evans WJ, Rodriguez NR, Johannsen NM, Gadde KM, Harris MN, Rood JC, Pasiakos SM. Howard EE, et al. Am J Physiol Endocrinol Metab. 2020 Oct 1;319(4):E678-E688. doi: 10.1152/ajpendo.00157.2020. Epub 2020 Aug 10. Am J Physiol Endocrinol Metab. 2020. PMID: 32776828 Free PMC article. - The Role of Estrogen Modulators in Male Hypogonadism and Infertility.
Rambhatla A, Mills JN, Rajfer J. Rambhatla A, et al. Rev Urol. 2016;18(2):66-72. doi: 10.3909/riu0711. Rev Urol. 2016. PMID: 27601965 Free PMC article. - Supraphysiological testosterone supplementation improves granulation tissue maturation through angiogenesis in the early phase of a cutaneous wound healing model in rats.
de Paiva Gonçalves V, Steffens JP, Junior CR, Spolidorio LC. de Paiva Gonçalves V, et al. Inflamm Res. 2022 Apr;71(4):473-483. doi: 10.1007/s00011-022-01553-7. Epub 2022 Mar 30. Inflamm Res. 2022. PMID: 35355085 - Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.
Fanelli F, Gambineri A, Mezzullo M, Vicennati V, Pelusi C, Pasquali R, Pagotto U. Fanelli F, et al. Rev Endocr Metab Disord. 2013 Jun;14(2):185-205. doi: 10.1007/s11154-013-9243-y. Rev Endocr Metab Disord. 2013. PMID: 23619762
References
- Simpson ER 2003 Sources of estrogen and their importance. J Steroid Biochem Mol Biol 86:225–230 - PubMed
- Meikle AW, Mazer NA, Moellmer JF, Stringham JD, Tolman KG, Sanders SW, Odell WD 1992 Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J Clin Endocrinol Metab 74:623–628 - PubMed
- Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F 2004 Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434 - PubMed
- von Eckardstein S, Nieschlag E 2002 Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419–425 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 5P30 AG31679/AG/NIA NIH HHS/United States
- 1R01AG31206/AG/NIA NIH HHS/United States
- P30 AG031679/AG/NIA NIH HHS/United States
- R01 AG031206/AG/NIA NIH HHS/United States
- 1 UO1AG14369/AG/NIA NIH HHS/United States
- U01 AG014369/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Miscellaneous